Seres Therapeutics (MCRB) Total Liabilities (2014 - 2026)
Seres Therapeutics (MCRB) posted Total Liabilities of $91.1 million for Q1 2026, down 3.04% sequentially from $94.0 million in Q4 2025, and down 19.87% YoY from $113.7 million in Q1 2025.
Seres Therapeutics (MCRB) Total Liabilities (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Total Liabilities for 13 years, with the latest figure at $91.1 million in Q1 2026.
- Quarterly Total Liabilities fell 19.87% year-over-year to $91.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.1 million (down 19.87% YoY) and the FY2025 annual result came in at $94.0 million, down 25.43% from the prior year.
- Total Liabilities slipped to $91.1 million in Q1 2026 per MCRB's latest filing, from $94.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $408.8 million in Q2 2024 and troughed at $91.1 million in Q1 2026.
- A 5-year average of $244.7 million and a median of $244.3 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 56.71% in 2023, then sank 72.88% in 2025.
- Over 5 years, Total Liabilities stood at $338.0 million in 2022, then gained by 19.37% to $403.5 million in 2023, then sank by 68.76% to $126.0 million in 2024, then retreated by 25.43% to $94.0 million in 2025, then fell by 3.04% to $91.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $91.1 million, $94.0 million, and $99.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Seres Therapeutics | 43.82 Mn | 43.82 Mn | - | 67.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.05 Mn |
| Mar 31, 2026 | 91.12 Mn |
| Dec 31, 2025 | 93.98 Mn |
| Sep 30, 2025 | 99.78 Mn |
| Jun 30, 2025 | 110.85 Mn |
| Mar 31, 2025 | 113.72 Mn |
| Dec 31, 2024 | 126.03 Mn |
| Sep 30, 2024 | 154.82 Mn |
| Jun 30, 2024 | 408.81 Mn |
| Mar 31, 2024 | 401.00 Mn |
| Dec 31, 2023 | 403.46 Mn |
| Sep 30, 2023 | 382.82 Mn |
| Jun 30, 2023 | 383.77 Mn |
| Mar 31, 2023 | 318.07 Mn |
| Dec 31, 2022 | 338.00 Mn |
| Sep 30, 2022 | 244.28 Mn |
| Jun 30, 2022 | 250.14 Mn |
| Mar 31, 2022 | 238.93 Mn |
| Dec 31, 2021 | 223.35 Mn |
| Sep 30, 2021 | 220.56 Mn |